Try our beta test site

Oral Melatonin in Critically Ill High-risk Patients

This study has been completed.
Information provided by:
University of Milan Identifier:
First received: May 4, 2007
Last updated: July 26, 2010
Last verified: January 2010
Sleep disruptions are extremely common in high-risk critically ill patients. The investigators want to analyse oral melatonin potentialities as a sedative and a free-radicals scavenger for critically ill patients, and secondarily for preventing Delirium during their ICU stay and post-traumatic stress disorders after ICU discharge.

Condition Intervention Phase
Critically Ill Patients
Mechanically Ventilated Patients
Drug: Oral melatonin 3mg BID
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin

Resource links provided by NLM:

Further study details as provided by University of Milan:

Primary Outcome Measures:
  • Overall sedatives daily doses [ Time Frame: Discharge from ICU ]

Secondary Outcome Measures:
  • Prevalence of Delirium assessed with CAM-ICU [ Time Frame: Discharge from ICU ]
  • Prevalence of mental disorders [ Time Frame: 60 days after ICU discharge ]
  • ICU length of stay [ Time Frame: Discharge from ICU ]
  • ICU mortality [ Time Frame: Discharge from ICU ]
  • Hospital mortality [ Time Frame: Hospital discharge ]
  • Sleep quantity assessed by wrist actigraphy [ Time Frame: Discharge from ICU ]

Enrollment: 96
Study Start Date: May 2007
Study Completion Date: May 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: A - placebo
Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
Drug: Placebo
Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
Active Comparator: B - melatonin
Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
Drug: Oral melatonin 3mg BID
Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
Other Name: MELATONIN 3 mg

  Show Detailed Description


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • High Treatment > 1 day
  • Normal gastrointestinal function

Exclusion Criteria:

  • Status asthmaticus
  • Chronic renal failure under dialytic treatment
  • Severe hepatopathy (Child-Pugh class = C)
  • Comatous patients (GCS < 12)
  • Head trauma, severe neurological diseases (ictus cerebri, SAH, ...)
  • Intoxicated patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00470821

Azienda Ospedaliera San Paolo - Polo Universitario
Milano, Italy, 20142
Sponsors and Collaborators
University of Milan
Study Chair: Gaetano Iapichino, MD University of Milan
  More Information

Responsible Party: Giovanni Mistraletti, MD, Istituto di Anestesiologia e Rianimazione, Università di Milano Identifier: NCT00470821     History of Changes
Other Study ID Numbers: Mela-UniMi-0001
Study First Received: May 4, 2007
Last Updated: July 26, 2010

Keywords provided by University of Milan:
critical patients

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants processed this record on March 28, 2017